Abstract
The purpose of this study is to evaluate the antiviral activity, clinical outcomes, safety,
tolerability, and pharmacokinetic/pharmacodynamic relationships of different oral dose levels
of JNJ-53718678 in children greater than or equal to 28 days and less than or equal to 3
years of age with respiratory syncytial virus (RSV) disease (hospitalized participants
[Cohort 1] or outpatients [Cohort 2]).
